Gain Therapeutics, Inc..
GANX.US | Research and experimental development on natural sciences and engineering
Gain Therapeutics, Inc. is a biotechnology company focused on developing novel therapies for neurodegenerative diseases and other serious conditions. The company's proprietary SEE-Tx platform identifies and optimizes allosteric modulators that restore protein function. Their lead programs target gen...Show More
Better Health for All
40
Gain Therapeutics' core business is entirely devoted to developing therapies for serious neurodegenerative diseases, specifically Parkinson's disease, with preclinical data suggesting its lead candidate, GT-02287, could restore lysosomal function and potentially slow or stop disease progression.
1
As a pre-revenue company with products in early clinical trials, it generates no revenue from products with negative health outcomes.
2
The company has demonstrated an outstanding safety record in its Phase 1 and Phase 1b clinical trials for GT-02287, with no serious adverse events reported across 72 healthy volunteers and 16 Parkinson's patients.
3
Gain Therapeutics shows a revolutionary commitment to health innovation, with significant funding from The Michael J. Fox Foundation, The Silverstein Foundation, Eurostars-2, and Innosuisse, indicating that its entire R&D budget is dedicated to improving health outcomes.
4
The Phase 1 clinical study received approval from the Bellberry Human Research Ethics Committee (HREC) in Australia, and the trial design is described as randomized, double-blind, and placebo-controlled, suggesting adherence to ethical clinical trial practices.
5
Fair Money & Economic Opportunity
0
Gain Therapeutics, Inc. is a biotechnology company focused on developing therapies for neurodegenerative diseases.
1
Its core business activities do not involve lending, insuring, moving, or storing money for consumers, nor does it offer financial products or services. Therefore, the company does not have customer financial data, APRs, fee structures, or financial inclusion programs to evaluate against the 'Fair Money & Economic Opportunity' KPIs. The company's reinvestment of profits is directed towards research and development for its therapies, not community finance.
2
All relevant KPIs are scored as '0' because they are not applicable to a company operating outside the financial services sector, as per the rubric's definitions.
Fair Pay & Worker Respect
0
No specific quantitative data for Gain Therapeutics (GANX.US) regarding fair pay and worker respect metrics was found in the provided articles.
1
The articles either focused on industry-wide trends or other companies, explicitly stating that no data for GANX.US was available for any of the assessed KPIs.
2
Fair Trade & Ethical Sourcing
0
No relevant data could be extracted from the provided articles to assess GANX.US against the Fair Trade & Ethical Sourcing value.
1
Both articles returned 404 errors, indicating the requested pages were not found.
2
Honest & Fair Business
0
The company has a formal whistleblower policy, introduced on December 5, 2022, specifically for accounting, internal controls, or auditing matters.
1
This policy mandates confidential and anonymous reporting through a third-party service provider.
2
Investigations are overseen by the Audit Committee and may involve outside counsel, with reports provided to the Audit Committee and designated management.
3
Records are retained for at least five years.
4
The policy is communicated to all staff via a confidential and anonymous financial concern hotline, as required by the SEC.
5
Kind to Animals
0
The provided articles state that Gain Therapeutics, Inc. uses animals for product testing.
1
However, no specific, concrete data points were found regarding the volume of animals used, the extent of alternative testing methods employed, the specifics of their animal testing policy, or any other animal welfare practices. Therefore, no KPIs can be scored against the rubric's quantitative thresholds.
No War, No Weapons
0
No specific, concrete data points were found in the provided articles to assess Gain Therapeutics (GANX.US) against any of the KPIs for the 'No War, No Weapons' ethical value. The articles consistently focus on the company's biotechnology operations, drug development activities, and clinical studies for neurodegenerative diseases, without any mention of involvement in arms manufacturing, military contracts, dual-use technologies, or peacebuilding initiatives.
1
Planet-Friendly Business
0
The provided articles for Gain Therapeutics, Inc. (GANX.US) primarily focus on financial performance, drug development, clinical trials, and general corporate information. They do not contain any specific, concrete data points or factual information related to environmental sustainability metrics such as greenhouse gas emissions, renewable energy use, water consumption, waste management, green building certifications, climate targets, or environmental compliance.
1
Therefore, it is not possible to assess the company against any of the 'Planet-Friendly Business' KPIs based solely on the evidence provided.
Respect for Cultures & Communities
0
The provided articles focus exclusively on Gain Therapeutics' clinical trial progress for GT-02287, regulatory approvals in Australia, and financial updates. There is no information or data available in the articles regarding the company's engagement with local or indigenous communities, cultural impact assessments, local employment, procurement, or any other metrics related to respect for cultures and communities.
1
Safe & Smart Tech
0
No specific, concrete data points were found in the provided articles regarding Gain Therapeutics, Inc.'s performance on any of the Safe & Smart Tech KPIs.
1
The articles discuss general industry trends in cybersecurity and regulatory compliance, or financial and clinical trial information about the company, but do not provide evidence directly attributable to GANX.US concerning data breaches, cybersecurity investment, privacy certifications, security training, encryption, AI ethics, data control, vulnerability management, or other related metrics.
2
Zero Waste & Sustainable Products
0
No evidence was found in the provided articles regarding Gain Therapeutics, Inc.'s performance on waste diversion, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design principles, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero waste certification, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education.
1